Raoul Herbrecht
About
In The Last Decade
Raoul Herbrecht
298 papers receiving 21.9k citations
Hit Papers
Peers
Comparison fields: 5 of 159
- Infectious Diseases 13.0k
- Epidemiology 11.3k
- Oncology 5.6k
- Pathology and Forensic Medicine 5.3k
- Genetics 2.5k
Countries citing papers authored by Raoul Herbrecht
This map shows the geographic impact of Raoul Herbrecht's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Raoul Herbrecht with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Raoul Herbrecht more than expected).
Fields of papers citing papers by Raoul Herbrecht
This network shows the impact of papers produced by Raoul Herbrecht. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Raoul Herbrecht. The network helps show where Raoul Herbrecht may publish in the future.
Co-authorship network of co-authors of Raoul Herbrecht
This figure shows the co-authorship network connecting the top 25 collaborators of Raoul Herbrecht. A scholar is included among the top collaborators of Raoul Herbrecht based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Raoul Herbrecht. Raoul Herbrecht is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 2 | |
| 2 | 1 | |
| 3 | 34 | |
| 4 | 7 | |
| 5 | 5 | |
| 6 | 31 | |
| 7 | 2 | |
| 8 | Function of Ikaros as a tumor suppressor in B cell acute lymphoblastic leukemia | 19 |
| 9 | 1 | |
| 10 | 258 | |
| 11 | 1 | |
| 12 | Bendamustine versus chlorambucil in treatment- naive patients with chronic lymphocytic leukemia: Updated results of an international phase III study | 1 |
| 13 | 1 | |
| 14 | 407 | |
| 15 | Final results of the efficacy and safety of rasburicase (recombinant urate oxydase) for the prevention and treatment of hyperuricemia in patients with aggressive lymphoma (GRAAL 1 study). | 4 |
| 16 | Randomised comparison of voriconazole and amphotericin B in primary therapy of invasive aspergillosis. | 11 |
| 17 | Standards, Options et Recommandations (SOR) pour la surveillance et la prévention des infections nosocomiales en cancérologie | 5 |
| 18 | Alternance of chemotherapy does not improve results in aggressive non-Hodgkin's lymphoma: A prospective randomized study on 884 patients LNH87 protocol group 3: A gela study | 2 |
| 19 | [Antibiotic strategy for febrile episodes during severe (less than 500 PNN) and prolonged (greater than or equal to 7 days) neutropenia. Recommendations of the Evaluation Committee of the Collège Français des Hematologistes]. | 1 |
| 20 | Alternating Chemotherapy Does Not Improve Results in Poor-prognosis Aggressive Lymphomas - Lnh87 Protocol Group-3 - a Gela Study | 2 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.